Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TONTT-2: Erythropoietin Dosing in Traumatic Optic Neuropathy
NCT03308448Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Jan 2018
- Primary completion
- Aug 2022
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of epoetin alfa in traumatic optic neuropathy (TON) (3 arms), sponsored by Iran University of Medical Sciences. Primary endpoint: Change in Mean LogMAR Best Corrected Visual Acuity at 24 months. Started Jan 2018; status: completed.
02
Drugs
epoetin alfa
03
Conditions
traumatic optic neuropathy (TON)
Beyond the preview
Go deeper on NCT03308448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03308448.